Total Payments
$1.1M
2024 Payments
$249,672
Companies
35
Transactions
1,988
Medicare Patients
755
Medicare Billing
$189,082
Payment Breakdown by Category
Other$937,746 (85.1%)
Travel$108,560 (9.8%)
Food & Beverage$43,472 (3.9%)
Consulting$12,155 (1.1%)
Gifts$178.54 (0.0%)
Education$161.92 (0.0%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $937,746 | 427 | 85.1% |
| Travel and Lodging | $108,560 | 501 | 9.8% |
| Food and Beverage | $43,472 | 1,036 | 3.9% |
| Consulting Fee | $12,155 | 8 | 1.1% |
| Gift | $178.54 | 6 | 0.0% |
| Education | $161.92 | 10 | 0.0% |
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alkermes, Inc. | $525,777 | 728 | $0 (2024) |
| ITI, Inc. | $192,661 | 264 | $0 (2023) |
| Sunovion Pharmaceuticals Inc. | $155,115 | 393 | $0 (2022) |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $109,681 | 113 | $0 (2024) |
| Janssen Pharmaceuticals, Inc | $74,737 | 152 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $15,198 | 59 | $0 (2022) |
| Allergan Inc. | $10,683 | 35 | $0 (2018) |
| Takeda Pharmaceuticals America, Inc. | $9,214 | 19 | $0 (2017) |
| Gilead Sciences, Inc. | $2,051 | 8 | $0 (2023) |
| Teva Pharmaceuticals USA, Inc. | $1,745 | 33 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $249,672 | 297 | Alkermes, Inc. ($139,093) |
| 2023 | $200,494 | 301 | Alkermes, Inc. ($122,468) |
| 2022 | $177,236 | 300 | Alkermes, Inc. ($89,661) |
| 2021 | $62,295 | 155 | Alkermes, Inc. ($39,250) |
| 2020 | $41,139 | 123 | ITI, Inc. ($14,905) |
| 2019 | $95,625 | 188 | Alkermes, Inc. ($51,686) |
| 2018 | $157,381 | 325 | Sunovion Pharmaceuticals Inc. ($74,803) |
| 2017 | $118,431 | 299 | Sunovion Pharmaceuticals Inc. ($40,061) |
All Payment Transactions
1,988 individual payment records from CMS Open Payments — Page 1 of 80
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/18/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $124.82 | General |
| Category: CNS | ||||||
| 12/13/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $26.43 | General |
| Category: CNS | ||||||
| 12/07/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $27.63 | General |
| Category: PSYCHIATRY | ||||||
| 12/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $2.25 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $247.90 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $194.78 | General |
| Category: PSYCHIATRY | ||||||
| 12/04/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $122.35 | General |
| Category: PSYCHIATRY | ||||||
| 12/03/2024 | Neurocrine Biosciences, Inc. | INGREZZA (Drug) | Food and Beverage | In-kind items and services | $27.47 | General |
| Category: Neuropsychiatry | ||||||
| 11/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $2,100.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/20/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $114.75 | General |
| Category: PSYCHIATRY | ||||||
| 11/19/2024 | Alkermes, Inc. | LYBALVI (Drug), LYBALVI, LYBALVI | Travel and Lodging | In-kind items and services | $1,039.88 | General |
| Category: CNS | ||||||
| 11/19/2024 | Vanda Pharmaceuticals Inc. | HETLIOZ (Drug), FANAPT | Food and Beverage | In-kind items and services | $18.15 | General |
| Category: NON-24-HOUR SLEEP-WAKE DISORDER | ||||||
| 11/19/2024 | Alkermes, Inc. | ARISTADA (Drug), ARISTADA, ARISTADA | Food and Beverage | In-kind items and services | $15.99 | General |
| Category: CNS | ||||||
| 11/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $4,200.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $792.94 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $219.94 | General |
| Category: PSYCHIATRY | ||||||
| 11/14/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $125.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/12/2024 | IDORSIA PHARMACEUTICALS US INC | QUVIVIQ (Drug) | Food and Beverage | In-kind items and services | $14.71 | General |
| Category: Insomnia | ||||||
| 11/07/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $1,680.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/07/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $7.16 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | Cash or cash equivalent | $3,360.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | In-kind items and services | $300.00 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Travel and Lodging | Cash or cash equivalent | $160.80 | General |
| Category: PSYCHIATRY | ||||||
| 11/06/2024 | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | CAPLYTA (Drug) | Food and Beverage | In-kind items and services | $122.79 | General |
| Category: PSYCHIATRY | ||||||
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 4 | 118 | 328 | $52,466 | $30,408 |
| 2022 | 7 | 172 | 429 | $74,937 | $43,159 |
| 2021 | 8 | 238 | 860 | $131,521 | $91,434 |
| 2020 | 7 | 227 | 333 | $64,115 | $24,082 |
Total Patients
755
Total Services
1,950
Medicare Billing
$189,082
Procedure Codes
27
All Medicare Procedures & Services
27 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2023 | 19 | 164 | $10,824 | $9,988 | 92.3% |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2023 | 17 | 61 | $10,064 | $9,361 | 93.0% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2023 | 49 | 50 | $19,600 | $6,283 | 32.1% |
| 99233 | Subsequent hospital care with moderate levelof medical decision making, if using time, at least 50 minutes | Facility | 2023 | 33 | 53 | $11,978 | $4,776 | 39.9% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2022 | 21 | 64 | $17,601 | $15,768 | 89.6% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2022 | 21 | 152 | $9,882 | $9,425 | 95.4% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 37 | 65 | $13,898 | $5,114 | 36.8% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2022 | 33 | 33 | $11,900 | $4,306 | 36.2% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Office | 2022 | 11 | 45 | $6,937 | $3,752 | 54.1% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Facility | 2022 | 19 | 27 | $5,945 | $1,989 | 33.5% |
| 99443 | Telephone medical discussion with physician, 21-30 minutes | Office | 2022 | 15 | 23 | $5,813 | $1,697 | 29.2% |
| 99232 | Follow-up hospital inpatient care per day, typically 25 minutes | Facility | 2022 | 15 | 20 | $2,962 | $1,106 | 37.3% |
| G0483 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms | Office | 2021 | 24 | 171 | $47,027 | $42,223 | 89.8% |
| 80307 | Testing for presence of drug, by chemistry analyzers | Office | 2021 | 28 | 413 | $26,849 | $25,664 | 95.6% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2021 | 62 | 91 | $18,382 | $7,217 | 39.3% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2021 | 43 | 43 | $13,674 | $5,872 | 42.9% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2021 | 23 | 48 | $10,608 | $4,203 | 39.6% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Office | 2021 | 19 | 39 | $6,981 | $3,404 | 48.8% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2021 | 25 | 30 | $4,200 | $1,635 | 38.9% |
| 99442 | Physician telephone patient service, 11-20 minutes of medical discussion | Office | 2021 | 14 | 25 | $3,800 | $1,216 | 32.0% |
| 99233 | Subsequent hospital inpatient care, typically 35 minutes per day | Facility | 2020 | 54 | 88 | $17,776 | $7,034 | 39.6% |
| 90792 | Psychiatric diagnostic evaluation with medical services | Facility | 2020 | 44 | 44 | $13,992 | $4,842 | 34.6% |
| 99232 | Subsequent hospital inpatient care, typically 25 minutes per day | Facility | 2020 | 44 | 69 | $9,660 | $3,848 | 39.8% |
| 99443 | Physician telephone patient service, 21-30 minutes of medical discussion | Office | 2020 | 24 | 44 | $9,603 | $3,602 | 37.5% |
| 99214 | Established patient office or other outpatient, visit typically 25 minutes | Office | 2020 | 26 | 40 | $7,292 | $2,643 | 36.3% |
About Dr. Kevin Ware, MD
Dr. Kevin Ware, MD is a Psychiatry healthcare provider based in Columbus, Ohio. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 06/09/2006. The National Provider Identifier (NPI) number assigned to this provider is 1609817980.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Kevin Ware, MD has received a total of $1.1M in payments from pharmaceutical and medical device companies, with $249,672 received in 2024. These payments were reported across 1,988 transactions from 35 companies. The most common payment nature is "Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program" ($937,746).
As a Medicare-enrolled provider, Ware has provided services to 755 Medicare beneficiaries, totaling 1,950 services with total Medicare billing of $189,082. Data is available for 4 years (2020–2023), covering 27 distinct procedure/service records.
Ad
Practice Information
- Specialty Psychiatry
- Location Columbus, OH
- Active Since 06/09/2006
- Last Updated 03/27/2008
- Taxonomy Code 2084P0800X
- Entity Type Individual
- NPI Number 1609817980
Products in Payments
- CAPLYTA (Drug) $302,342
- LYBALVI (Drug) $279,720
- ARISTADA (Drug) $171,622
- LATUDA (Drug) $154,961
- Aristada 441 mg (Drug) $71,539
- INVEGA TRINZA (Drug) $44,031
- INVEGA SUSTENNA (Drug) $26,991
- Trintellix (Drug) $23,687
- VRAYLAR (Drug) $10,796
- SPRAVATO (Drug) $3,777
- Epclusa (Drug) $1,981
- AUSTEDO (Drug) $1,195
- Vivitrol (Drug) $957.56
- TRINTELLIX (Drug) $562.49
- Auvelity (Drug) $554.98
- NUPLAZID (Drug) $554.41
- REXULTI (Drug) $510.82
- Xyrem (Drug) $504.06
- Equetro (Drug) $306.90
- Austedo XR (Drug) $283.28
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Psychiatry Doctors in Columbus
Fred Romeo, Md, MD
Psychiatry — Payments: $2.3M
Psychiatry $2.3M
Michael Saribalas
Psychiatry — Payments: $1.3M
Psychiatry $1.3M
Dr. Peter Zafirides, Md, MD
Psychiatry — Payments: $127,832
Psychiatry $127,832
Dr. Benjamin Roy, M.d, M.D
Psychiatry — Payments: $102,125
Psychiatry $102,125
Barbara Gracious, M.d, M.D
Psychiatry — Payments: $58,986
Psychiatry $58,986
Dr. Pavan Dontineni, M.d, M.D
Psychiatry — Payments: $32,829
Psychiatry $32,829